GlassScriptPhysician profile
Samantha Criswell
NPI 1417764002
$625.26
in general payments reported to CMS, 2019-2025
14 companies · $625 in 2025
The $625 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.08 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $62.69 | 2025 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $46.39 | 2025 | Ohtuvayre |
| Seqirus USA INC | $44.60 | 2025 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $33.79 | 2025 | |
| Glaxosmithkline, LLC. | $33.37 | 2025 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $30.25 | 2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $29.51 | 2025 | |
| Axsome Therapeutics, INC. | $22.83 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.79 | 2025 | Xifaxan |
| Dexcom, INC. | $21.63 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $20.39 | 2025 | Veozah |
| Alnylam Pharmaceuticals INC. | $20.15 | 2025 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $14.79 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Criswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.